Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Dl-Tartaric acid became known to early chemists through the winemaking process, where it appeared as deposits in casks. Early records from the 18th century detail how winemakers noticed crystalline formations—later recognized as tartaric acid—clinging to the insides of barrels after fermentation. Over time, the science community began extracting and purifying this compound, which led to its entrance into pharmaceutical and industrial domains. Scientists like Carl Wilhelm Scheele and Louis Pasteur made key discoveries around tartaric acid’s stereoisomerism, directly influencing later research on chirality in organic molecules. The synthetic creation of the racemic form, known as dl-tartaric acid, marked a shift from purely natural extraction towards controlled laboratory methods, allowing for consistent quality and safety standards demanded by today’s pharmacopeia guidelines in BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia).
Dl-Tartaric acid appears as a white, odorless crystalline powder, soluble in water and alcohol, making it a useful agent in pharmaceuticals where both taste modification and buffering are crucial. Whether in effervescent tablets or in stabilizing specific medicinal compounds, dl-tartaric acid finds itself woven into hundreds of modern formulations. The racemic mixture—unlike the pure l or d forms—offers unique reactivity. Its availability in pharma grade underscores strict controls around purity and contaminant levels, supporting sensitive applications like injectable preparations. Manufacturers, pharmacists, and quality control analysts all work hands-on with this compound, insisting on certificates of analysis with every purchase to guarantee reliable therapeutic use.
Each molecule of dl-tartaric acid holds dual carboxylic acid groups and two hydroxyl groups on adjacent carbons. This structure makes it both a decent acidulant and chelating agent. It melts around 206°C with decomposition, signaling adequate heat resilience during manufacturing. The molecule’s chiral centers, despite being mixed racemically, can influence crystallization behavior and solution properties. Solubility sits at around 1g per 0.8ml of water, which means rapid dissolution, a favorite trait among formulators looking to shorten processing times. The molecular weight comes in at 150.09 g/mol; the IUPAC name remains 2,3-dihydroxybutanedioic acid. A characteristic tart taste makes it a good fit for oral pharmaceuticals looking to mask less pleasant flavors.
Pharma grade dl-tartaric acid claims a purity exceeding 99%, confirmed by analytical techniques such as HPLC and titration. Specifications dictate limits for heavy metals, typically under 10ppm for lead and other metals often associated with environmental contaminants. Sulfated ash percentage, often required to stay under 0.05%, gives a window into inorganic residue. Moisture content checks, usually performed by Karl Fischer titration, keep degradation threats in focus. Pharmacopeial monographs detail physical description, identification tests (such as IR spectroscopy), and microbial limits. Labels reflect batch number, manufacture date, retest/expiration date, storage conditions, and a declaration of compliance with current BP, EP, or USP guidelines, all set to reassure downstream handlers and regulators.
Most commercial dl-tartaric acid arises from chemical synthesis rather than extraction from wine residues. The mainstream method uses maleic anhydride as the starting material, undergoing catalytic oxidation to give racemic tartaric acid. The process runs under aerated conditions with vanadium pentoxide as a catalyst, followed by neutralization, purification, and crystallization. Experienced chemical engineers monitor these steps closely, watching for yield drops caused by contamination or poor pH control. Some facilities have experimented with biotechnological routes by fermenting carbohydrates using specific molds, but chemical synthesis dominates due to predictable output and scale. Quality assurance staff test each batch for unwanted side-products, safeguarding the final product’s safety profile.
Dl-Tartaric acid leads a double life in organic synthesis and as a reactant in coordination chemistry. Laboratory chemists regularly use it to resolve racemic amines or create optically active complexes by exploiting its chiral centers. Reacting with metal ions—such as calcium, potassium, or sodium—dl-tartaric acid forms salts used as emulsifiers, anticoagulants, or even as anti-caking agents in food and pharmaceuticals. Under heat, it undergoes decarboxylation or dehydration, producing compounds like pyruvic or tartaric anhydride. With oxidants, it breaks down to glyoxylic acid and CO₂, processes sometimes relevant during stability studies of pharmaceutical dosage forms. Skillful modification, such as esterification, turns it into valuable intermediates for specialty chemistry used in the synthesis of advanced drug molecules.
Besides dl-tartaric acid, this compound lands on order lists as Racemic tartaric acid, 2,3-Dihydroxybutanedioic acid, or Tartaric acid, dl-form. Some suppliers print it as “Race” tartaric acid, distinguishing it from the natural, optically active forms. Trade names and in-house codes populate technical sheets from different manufacturers; regulatory submissions often use the chemical abstracts number (CAS) 133-37-9 to avoid ambiguity. In pharmaceutical settings, technicians spot it noted as E334—its code as a food additive—on certain excipient documentation, making it familiar across industries.
Factories keep strict routines around handling and storage. Although tartaric acid rates as a low-toxicity compound, dust generation brings lungs and eyes into play. Material Safety Data Sheets (MSDS) urge handlers to use gloves, goggles, and dust masks. Quality labs routinely set personal air monitoring when weighing out larger batches, relying on local exhaust systems to minimize inhalation risk. At the same time, employers train staff on correct spill management, neutralizing any powder with dilute alkali and flushing residues with large water volumes. Warehouses store it in cool, dry, well-ventilated areas, sealed tightly to resist moisture pick-up that would degrade quality and promote clumping. Regulatory auditors look for clear lot separation, good documentation practices, and immediate access to safety data. Waste management systems funnel contaminated water and packaging into approved chemical disposal streams, attentive to environmental obligations.
Pharma grade dl-tartaric acid claims a spot beyond the pharmaceutical laboratory. It finds its way into effervescent oral formulations, where it provides the acidic half of the reaction with sodium bicarbonate, generating pleasant fizz and improving taste. In the tablet compression world, tartaric acid modifies pH and helps certain drugs dissolve faster in the digestive tract. Some manufacturers rely on it as a buffering agent for injectable solutions, where it anchors pH tightly within therapeutic ranges. Dental products, syrups, and chewable vitamins often list dl-tartaric acid both for its flavor and its gentle acidity. Food and beverage industries see value through the E334 additive number, popping up in soft drinks and cream of tartar. Recent years have seen veterinary products and even cosmetics draw on dl-tartaric acid for its dual role in stabilizing actives and modifying taste or rheology.
Research into dl-tartaric acid keeps evolving. Many scientists probe its abilities as a chiral selector in chromatographic systems, looking to advance drug purity and separation techniques. Chemical engineers keep refining the synthetic processes, aiming for smaller carbon footprint and optimized catalyst recycling. In pharmaceutical science labs, researchers test tartaric acid analogs for new roles, such as stabilizers for challenging proteins or biologic formulations, recognizing the need for advanced excipients as biologics grow. Environmental researchers push for green chemistry routes for dl-tartaric acid, evaluating advances in biocatalytic synthesis. Quality specialists run stress tests on tartaric-acid-containing drugs to map out degradation profiles, hopeful that this knowledge can improve packaging and shelf life. Study of tartaric acid salts broadens its horizons, opening the door for applications in anticoagulation and electrolyte balance in clinical nutrition.
Toxicologists have investigated dl-tartaric acid thoroughly. Animal model studies place its oral LD50 in rats above 5g/kg, showing a relatively low risk of acute poisoning. Repeated exposure through oral, dermal, or inhalational routes has generated little evidence of carcinogenicity or genotoxicity. Regulatory bodies have set Acceptable Daily Intake (ADI) based on long-term dietary exposure data, referencing both natural sources and pharmaceutical formulations. Some rare cases point to gastrointestinal upset in humans who ingest excessive amounts, but at recommended doses in medications, the compound remains well tolerated. Dermatological patch tests, usually negative, underscore its suitability in topical products. Occupational health teams monitor manufacturing staff for chronic respiratory symptoms, but adherence to modern safety standards keeps this risk low. The environmental fate of dl-tartaric acid, shaped by biodegradability, means that it typically breaks down well in wastewater treatment systems, limiting its ecological impact.
The horizon looks promising for dl-tartaric acid, as pharmaceutical companies look for well-understood, reliable excipients while pressure builds to limit reliance on petroleum-derived chemicals. Advances in biotechnological production, using engineered microbes to crank out tartaric acid in fermentation reactors, promise improved sustainability. Analytical chemists continue to employ tartaric acid derivatives in chiral separations, especially as new chiral drugs enter the market. Ongoing refinements in quality control, including rapid spectroscopic fingerprinting and in-process monitoring, help reduce batch failures and improve safety profiles. Emerging markets, eager for robust and affordable pharma excipients, strengthen global demand. Specialty manufacturers invest in new grades, such as ultra-low metal versions aimed at injectable and pediatric drugs. Applications in food, cosmetics, and green chemistry further broaden the footprint of dl-tartaric acid, ensuring its place in a landscape that values both function and established safety.
Dl-Tartaric acid does its best work away from the spotlight. Stepping into a pharmaceutical facility, I’m reminded how many small ingredients quietly support the health system. This compound, described by many as a dibasic acid, holds recognized pharmaceutical grades such as BP, EP, and USP, signaling that it meets tough standards for use in medication and health products. It’s not some generic food additive—it plays a unique part in keeping pills stable and giving tablets their structure.
Anyone who’s ever handled a pill has probably experienced the results of tartaric acid’s presence. Many medications need to maintain their shape, resist breaking too soon, but also fall apart right when expected in the stomach or mouth. Dl-Tartaric acid helps form the matrix that makes all this possible. It’s what keeps tablets cohesive, offers a consistent taste, and helps active ingredients blend evenly. Without it, medicine manufacturing would feel a lot like baking bread without yeast—maybe possible, but certainly not as reliable.
The tough pill-swallowers of the world may not mind, but taste matters, especially in chewables and syrups. Dl-Tartaric acid brings a clean, sharp tartness that can mask unpleasant flavors. Looking at children’s syrups or antacid tablets, you often taste its subtle punch, smoothing out metallic or bitter notes. This experience makes a difference for patient compliance—if medicine tastes better, people are more likely to keep taking it as directed.
Beneath the flavors and textures, Dl-Tartaric acid acts as an acidulant, adjusting pH to help sensitive ingredients stay stable. Certain antibiotics, vitamins, and amino acids don’t keep well at high or erratic pH levels. By stabilizing the environment inside a tablet or powder, this acid keeps formulas consistent throughout their shelf life. Regulatory authorities like the FDA and EMA don’t just recommend this—they expect it.
Every time a manufacturer picks a batch of Dl-Tartaric acid, plenty rides on that decision. Pharma grade—whether BP, EP, or USP—means the compound passes through strict quality checks for identity, purity, and chemical properties. Not all tartaric acid makes the cut. Crooked sourcing, trace contaminants, or poor handling all risk people’s health. Stories of recalls linked to ingredient quality show why careful sourcing and testing matter so much.
From my experience, better traceability stands out as a solution. Modern pharma companies now track every lot of ingredients like Dl-Tartaric acid from origin to finished product. Blockchain technology and digital records offer new levels of transparency, so nobody has to wonder about the chain of custody. In a world where drug safety worries keep growing, every trusted batch of tartaric acid means one less point of failure.
It’s easy to overlook these behind-the-scenes agents, but they give us reliable, effective medicine day after day. By keeping a close eye on the quality and traceability of such ingredients, we help protect everyone who relies on pharmaceuticals—young, old, healthy, or chronically ill.
Dl-Tartaric Acid isn’t just a bland chemical name. In the world of pharmaceuticals, every detail about this compound means a lot. Pharmaceutical grade tells you purity hits a higher mark compared to industrial or food grades. The “BP EP USP” labeling means this tartaric acid aligns with three major pharmacopeia benchmarks — British (BP), European (EP), and United States (USP). That’s the level of scrutiny you want in anything that ends up in medicine for humans.
Over the years, I've watched corners cut on non-pharma ingredients, but not here. Dl-Tartaric Acid for pharma always lists purity at 99% or higher. That 1% leftover shouldn’t include anything that puts pills, injectables, or syrups at risk. Moisture usually stays below 0.5%. The melting point often sits around 200°C, so it won’t break down at reasonable processing temperatures. Sulphated ash — a sign of unwanted residues — must come in at 0.1% or less. In a factory using hundreds of kilos, that sort of precision isn’t just academic.
Measured content: 99% to 101%, dry basis. This isn't a marketing number; this comes from titration and chromatography that would hold up to outside audits. Heavy metals? Below 10 ppm is standard. Lead lurks as a real contaminant in some manufacturing pipelines, so any trace amount gets flagged. Chloride and sulfate numbers need to be under tight limits — under 100 ppm is common — because those disrupt tablets and can trigger reactions in sensitive patients.
Companies have a duty to keep things safe and consistent. Patients can’t afford to wonder if the next batch of medicine will dissolve the same or upset their stomachs. Too much acid, or the wrong impurities, and you see tablets break down too fast or not at all. Even small impurities sometimes set off allergic reactions, which hits close to home for many of us, especially with kids or elders in the family who need regular medication.
Good labs don’t skimp on routine testing. Regular IR spectroscopy, loss-on-drying tests, and heavy metal checks keep the chain honest. Suppliers who skip steps or fudge numbers can ruin reputations. A single failed batch can mean hundreds of thousands in wasted pills, plus health risks that follow patients far beyond the factory fence.
Choosing qualified suppliers is the first real filter. Third-party audits add another layer. Investing in staff training so every technician knows the limits — not just reading but understanding why 0.1% ash matters — cuts mistakes upstream. For manufacturers, good record-keeping and real-time batch-release testing keep slip-ups small and rare.
Dl-Tartaric Acid may just seem like a white powder. The moment it becomes part of a pharma product, it carries the safety, trust, and outcome of real people. Purity and exacting specifications bridge the difference between a product that helps and one that harms. That’s not negotiable in healthcare.
In my years working in the pharmacy field, safety always stands out as the top requirement for anything used in medicines. Dl-Tartaric acid with BP, EP, and USP grades often gets attention for its purity and consistent results. These grades mean the ingredient gets tested and handled using rules from respected sources—the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP). For pharmaceutical companies, these aren’t just letters at the end of a compound's name—they serve as reassurance that strict standards have been met.
Dl-Tartaric acid pops up in many medicines because it helps control pH, works well as a stabilizer, and keeps medicine mixed together. Sometimes it comes up in tablets to help with the breakdown and absorption of active substances. People outside the chemistry world might not realize how much effort goes into checking each step of production. For each batch, labs run thorough tests to check for impurities, heavy metals, and unwanted by-products. Those test results get checked during audits by health authorities, making shortcuts almost impossible.
Factories making BP/EP/USP-grade Dl-Tartaric acid follow procedures that leave little to chance. They trace everything from raw materials to packaging. Take audits—inspectors show up both announced and unannounced, review cleanliness logs, and verify traceability from start to finish. Any batch that misses a mark gets rejected before it ever leaves the warehouse. If you see news stories about tainted medicines, nine times out of ten, the culprit wasn’t following such standards.
I've seen cases where generic manufacturers try to cut costs using lower-grade ingredients. Problems start to appear—tablets break too easily, or worse, contain unwanted contaminants. The cost of recalls and potential harm to patients often far outweigh the savings. Dl-Tartaric acid with a pharma-quality label doesn’t come cheap, but skipping that step risks credibility and safety. In a nutshell, paying for BP/EP/USP grade gives an extra layer of protection. In my own experience with both small and big pharmaceutical companies, those that take short cuts often end up paying more in the long run with product recalls and loss of trust.
No ingredient stands alone in a finished medicine. Dl-Tartaric acid itself rarely causes problems at approved doses. It’s naturally found in food like grapes and bananas. Regulatory agencies review safety data from both animal studies and real-world use. Pharmacists look at possible issues when new formulas hit the shelves, but at pharmaceutical grade, risks stay low as long as the finished medicine is used as directed. Careful review doesn’t stop at the raw ingredient; every finished product passes through clinical testing and regulatory scrutiny before reaching patients.
Ongoing updates to standards, regular training for quality-control staff, and transparency in ingredient sourcing keep scrutiny high. With stiff penalties for not following rules, most major suppliers opt for full compliance. If more companies demand audit records and third-party lab results, safety climbs even higher.
In pharmacy and medicine, every shortcut risks someone’s health. For Dl-Tartaric acid with pharmaceutical grade markings, sticking to BP, EP, and USP standards helps keep trust, safety, and quality at the heart of every prescription.
Dl-Tartaric Acid sits on shelves in pharmaceutical labs and factories for good reason. Quality drugs and reliable results rely on safe handling of every ingredient including acids like this. Mishandling or storing tartaric acid the wrong way can lead to contamination and even health risks for anyone in proximity.
I’ve walked through more than a few warehouses and storage rooms. Each time, the most professional setups share a few traits: clean, dry shelves, clearly labeled containers, and zero clutter. Dl-Tartaric Acid demands just that level of care.
A cool, dry spot works best. If moisture sneaks in, tartaric acid cakes, clumps, and can degrade. That means inaccurate measurements and uncertain results in high-stakes labs. Dampness also breeds microbes and mold, which simply shouldn’t be part of any pharmaceutical product. Always use tightly sealed, inert containers—typically high-grade plastic, glass, or coated metal—so outside air and water can’t reach the acid. Keep acids like this off the floor and away from direct sources of heat or sunlight, both of which speed up breakdown and make the powder harder to work with.
Safe storage goes hand in hand with smart handling. Anyone scooping, pouring, or moving this powder should put on gloves, goggles, and a dust mask or a respirator. Even if Dl-Tartaric Acid doesn’t look threatening, inhaling its dust or exposing skin to the powder can cause irritation. Eye protection stays just as important—one careless motion and powder could scatter as fine dust.
Cross-contamination turns up far too easily, especially in pharmaceutical shops juggling lots of ingredients. Always use tools and scoops reserved for tartaric acid alone. Staff training makes a difference here. Discussing safe work practices in person matters more than a list taped to the door. During my time on the production floor, I watched teams cut down on mistakes all because they knew why the rules mattered.
No matter how careful a team works, powder spills happen. Quick cleanup stops accidental exposure and keeps product batches pure. Use a dedicated vacuum or scoop up the powder and seal it in a sturdy container for disposal as chemical waste. Avoid sweeping, which raises dust. If any part of the skin contacts the acid, wash immediately with clean water.
Gloves and other disposable gear head to chemical waste streams—not regular trash. Anyone who’s gotten the powder in their eyes or mouth should get medical help straight away, even if the irritation feels minor at first.
Successful labs, both large and small, keep detailed records on every batch of incoming chemicals, including storage conditions, expiration dates, and inspection notes. Dl-Tartaric Acid isn’t different. Regular checks for clumping, discoloration, or odd smells will catch problems early. Taking these steps also backs up a company’s quality and safety claims, which regulators and customers both demand.
Making the right call on where to buy matters long before the acid enters a lab. Review supplier audit reports and customer feedback. Ask how they store and ship Dl-Tartaric Acid and request batch-specific data. Partners who care about safe handling show that through proper transport, labeling, and transparency.
Reliable sourcing shapes every good outcome in the pharmaceutical industry. Dl-Tartaric Acid, when labeled BP, EP, or USP, must match the specifications those pharmacopeias spell out. Pharmacies, labs, and manufacturers lean on a Certificate of Analysis—COA—to show not just compliance, but genuine proof that what’s being bought upholds quality, traceability, and safety standards.
Any reputable supplier offering Dl-Tartaric Acid for pharmaceutical use should never shy away from providing a COA. Skipping the COA spells shortcuts. Regulatory auditors seek this proof. By showing physical records, a company proves batches fall within strict limits for purity and contaminants.
Years of working in pharma supply chains reinforce one simple lesson: documentation drives trust. I have seen sourcing teams walk away from good deals when the COA attached looks flimsy, photocopied, or incomplete. I’ve also listened to production supervisors fret when an incoming batch shows up with outdated analysis, which means delays and expensive third-party testing just to check purity and the presence of heavy metals or residual solvents.
Dl-Tartaric Acid is no exception to these requirements. It plays a crucial role in tablets and as a chiral resolving agent. Slight deviations in its chemical makeup can mess with drug safety or stability. If you’re responsible for quality assurance, you know a COA is not a box to tick. You look at water content, assay, appearance, pH, heavy metal traces—each aligned with the relevant pharmacopeia.
For years, regulatory agencies from the FDA to local drug controllers have tightened scrutiny on raw material documents. The COA not only lists test results for that specific batch, but includes production and expiry dates, tested grades, and methods used. This all matters if a recall hits, or a drug’s shelf life gets questioned. Without strong documentation, explanations get thin and liabilities skyrocket.
More buyers, both large and small, want to see validated analytical methods used for COA data. They don’t accept a handful of numbers typed onto a sheet. They expect references to HPLC, UV, or titration methods, each traceable to standards and audit logs. A supplier claiming “pharma grade” Dl-Tartaric Acid, yet providing no serious COA, does not inspire confidence or meet the standards set by regulators or end users.
The fix starts with choosing suppliers who treat paperwork as seriously as the product itself. Good partners, often certified to ISO 9001 or similar standards, link every drum or bag to lab-tested data. They archive supporting records and stand ready to answer questions if a batch needs tracking months or years later. Firms taking part in GxP compliance or registering with DMFs in the USA usually set the bar for documentation and long-term support.
Trust flows from openness. End users, buyers, and regulatory officials get peace of mind when every batch of Dl-Tartaric Acid comes with a genuine, batch-specific COA. This practice signals care, professionalism, and a commitment to patient safety on every level.
| Identifiers | |
| DrugBank | DB03793 |
| Properties | |
| log P | -2.95 |
Chengguan District, Lanzhou, Gansu, China
